Byetta Lawyer in Atlanta, GA
Byetta is an injectable medication that is used for the treatment of Type II diabetes. Byetta is classified as a gulcogon-like peptide – 1 or GLP1 and works in the gastrointestinal system of the body by increasing insulin production in the gut. Similar medications of this type include Januvia and Victoza.
Dangers Associated With Byetta
The Association of Safe Medication Practices released a report on April 18, 2013 that stated that there is significant evidence showing that use of GLP-1 medications, especially in injectable form, gives the patients an increased risk of acquiring pancreatitis, pancreatic and thyroid cancer.
In their report researchers provide evidence that patients using injectable GLP-1 medications doubled their risk of having thyroid tumors and developing thyroid cancer. They conducted this study as a result of finding information from the pharmaceutical company that shows lab rats were developing thyroid tumors during clinical trials of Byetta.
In the previous month, the Food and Drug Administration (FDA) released a Drug Safety Communication stating that there has been increased incidence of pancreatitis and pancreatic cancer in patients taking Byetta and similar GLP-1 medications. The report stated that pancreatic tissues removed from patients using this medication showed “marked changes in tissue construction, cellular changes and inflammation.”
Pancreatitis is a condition that causes inflammation of the pancreas tissues. This inflammation is very painful, can cause patients to be continually nauseous to the point of not being able to eat, and in extreme cases lead to death. Reoccurring bouts of pancreatitis has also been linked to the onset of pancreatic cancer. Pancreatic cancer is a very aggressive form cancer that has a very low cure rate.
The increased incidences of thyroid tumors and cancer has already been confirmed by the FDA and the agency now requires that the makers of Byetta list in their medication pamphlet the associated risk of thyroid cancer with medication use.
Now, after much review, the FDA is also requiring the drug manufacturers to include information surrounding pancreatitis and pancreatic cancer risks with their medication.
Due to the high number of adverse incidences associated with Byetta and similar GLP-1 medications, the FDA announced that it will be closely reviewing all the new research surrounding these medications and make a determination in the near future about their continued use.
At this time, any person who is taking Byetta or similar diabetes medication should closely monitor their health and contact their physician if any symptoms occur that seem unusual. If you have already shown symptoms of pancreatitis or thyroid problems, you may wish to speak to your doctor to see if using this medication is still advisable.
Related information: Januvia Lawsuits